

Anti-Gastric Inhibitory Polypeptide (GIP)**Mouse monoclonal antibody**

Subclass: IgG1/k

CAT. NO.

ABS 021-04

Clone: 4

SPECIFICITY	ABS 021-04 binds human GIP. ABS 021-04 cross-reacts up to 10% with PACAP and human GLP-2 but <0.1% with glucagon, GLP-1 or VIP.
IMMUNOGEN	Synthetic human gastric inhibitory polypeptide
TESTED APPLICATIONS	ELISA, IHC
SPECIES REACTIVITY (POSITIVE)	Human
SPECIES REACTIVITY (NEGATIVE)	Not determined
EPITOPE SPECIFICITY	Not determined

PRESENTATION

Content:	Available in 400 µL and 1 mL size. 1 mg/mL +/- 15%. See Certificate of Analysis for details.
Preparation:	Protein-A purified
Form:	Liquid
Solvent:	0.01 M phosphate buffer, pH 7.4, containing 0.5 M NaCl and 15 mM sodium azide
Storage:	4-8°C without exposure to light. No precautions necessary during handling.

APPLICATION

ELISA: With GIP coated directly at 2 µg/mL the dilution guideline is 1/2000. In addition ABS 021-04 binds free GIP in solution.
IHC: ABS 021-04 can be used in IHC. Please consult www.proteinatlas.org

TARGET

Human gastric inhibitory polypeptide (GIP) is a 42 amino acid peptide belonging to the glucagon-secretin family of peptide hormones. It is secreted by endocrine cells in the duodenal mucosa and stimulates glucose-dependent insulin secretion as well as GLP-1 release from more distal endocrine (L) cells in the intestinal mucosa.
GIP shows amino-acid sequence similarities to glucagon, GLP-1 and GLP-2 (from approximately 50% identity for glucagon to 30% identity for GLP-2).

REFERENCES**CONDITIONS**

Unless otherwise marked, all products are for research use only. Not for use in diagnostic procedures. Not for use in human therapeutic applications. For in vitro use or further manufacture only. The information and product are offered without guarantee as the ultimate conditions of use are beyond our control. The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics A/S be responsible for loss of profits or indirect consequential losses resulting from use of its products.